GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. - Wikidata - wikimedia - TriplyDB

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

http://www.wikidata.org/entity/Q38055195

about

Brain delivery of proteins via their fatty acid and block copolymer modifications Agile delivery of protein therapeutics to CNS GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Integration of satiety signals by the central nervous system.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.Cardiovascular safety and benefits of GLP-1 receptor agonists.Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?

P2860

Q30354932-E581C9BB-836C-46E3-9D6B-7C27CEF2D71B Q34079647-63C2A24F-14AE-4E50-8FD5-373F571DB309 Q36406821-BEED33A5-BEAC-4D3F-AA6A-3319517E5E56 Q36803151-C15C05CA-1984-4F33-A6A3-9D564C379F35 Q38105423-B131BABC-9C46-401D-A23C-048BF751C346 Q38199526-B7CDA9E3-8587-474F-A508-A5C8D777E8E2 Q38235219-F153BD1F-D0E8-48E6-AB4E-BF32A8F7E9BD Q38236774-099C3404-F603-4B7E-907D-72D0909091B2 Q38286444-B942915B-29E1-4EA2-AB60-B64869AEBEBC Q38606170-36E43540-ECCC-4E11-B0BC-7101B6942ED2 Q39013056-8513EB30-9781-4AA6-B90C-291822ED5E96 Q39204459-AAD7AA2D-3F3E-495A-8D47-FA5A1BDDEF6C Q42648850-CCF0645D-0828-457F-BBDB-A05435A3D8D2

P2860

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

http://www.wikidata.org/entity/Q38055195

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

@en

type

label

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

@en

prefLabel

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

@en

P1433

Q38055195-F156B316-07CE-4368-8ECE-426E8E90B876

P1476

Q38055195-F798900A-95B7-4642-8E00-D4B79A531388

P2093

Q38055195-4784A519-06FB-401A-BEA8-220F353BDD26

P2860

Q38055195-0BB9090E-A65D-4F77-BE8D-F71CB2B88B51

Q38055195-0C5A62A1-08FC-46D1-9DEA-E41427E2F367

Q38055195-0D696DFF-7CEF-46C7-9914-3D67824A3A60

Q38055195-0D7EBE2D-FEE9-4CCF-95FF-9EBF34E153E3

Q38055195-1079CC0D-AE4E-4F83-84BA-201CFD8CEA9D

Q38055195-11392AD2-1980-4A2F-B07E-D39CC4422035

Q38055195-1381F693-39A0-457C-9FC7-736B1F91666B

Q38055195-147E561C-B7B3-415A-A26C-BA1397F1280E

Q38055195-1A72E73B-5BDE-4250-B439-7A1A33F7D012

Q38055195-1EBAA083-F002-41D2-BFDA-FD347931D6AB

P304

Q38055195-1BC0642F-13C9-4AF0-A6BF-C83AFDADE616

P31

Q38055195-25372F73-0FF6-4941-8817-74C22828A589

P356

Q38055195-7E7B2E9B-2A42-4BD2-93D5-D2673A0DED9C

P407

Q38055195-EC2D61C5-CB0F-4A12-B815-A9725BD55CCB

P433

Q38055195-F8FA7406-DBBE-4789-A28D-FD24634F1B2E

P478

Q38055195-4078E301-A132-4C9D-B1C0-BCCFE0FE301C

P50

Q38055195-0C820DCE-E1BE-48D5-8B15-741965D553E7

Q38055195-D1552084-4A10-49F8-A85E-2F8778BEA06E

P577

Q38055195-F2B28C76-290B-401A-BAEC-170D9E4C81E6

P5875

Q38055195-CEE46D46-34D5-442E-BC3C-85796ECA366F

P698

Q38055195-F28704C3-79E7-440C-B794-2AFA3DBF00F2

P921

Q38055195-778D05E2-5F08-439A-8492-E8508A236CD7

P356

17425255.2013.731394

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations

@en

P2093

Maria J Jespersen

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

The Physiology of Glucagon-like Peptide 1

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

P304

17-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.731394

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Mikkel Christensen

P577

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232698054

http://www.w3.org/2001/XMLSchema#string

P698

23094590

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes